Skip to main content

Table 3 Subgroup analysis of exacerbations

From: Corticosteroid plus β2-agonist in a single inhaler as reliever therapy in intermittent and mild asthma: a proof-of-concept systematic review and meta-analysis

Comparisons Exacerbations Severe exacerbations
No. of Studies ICS/FABA FABA or ICS RR (95% CI) P value Power No. of Studies ICS/FABA FABA or ICS RR (95% CI) P value Power
ICS/FABA vs. FABA regimen
 All 4 [17, 27, 29, 30] 42/348 68/295 0.56 (0.40, 0.78) 0.001 1.00 3 [17, 27, 29] 25/238 41/239 0.64 (0.44, 0.95) 0.026 0.89
 Adult 2 [17, 27] 6/167 26/165 0.24 (0.10, 0.54) 0.001 0.98 2 [17, 27] 0/167 5/165 0.17 (0.02, 1.35) 0.093 0.47
 Children and adolescent 2 [29, 30] 36/181 42/130 0.76 (0.53, 1.10) 0.147 0.76 1 [29] 25/71 36/74 0.72 (0.49, 1.07) 0.107 0.34
ICS/FABA vs. ICS regimen
 All 4 [17, 26, 29, 30] 111/553 79/537 1.39 (1.08, 1.79) 0.011 1.00 3 [17, 26, 29] 94/443 70/427 1.34 (1.02,1.75) 0.034 0.91
 Adult 1 [17] 6/122 9/106 0.58 (0.21, 1.57) 0.284 0.17 1 [17] 0/122 3/106 0.12 (0.01,2.38) 0.166 0.22
 Children and adolescent 3 [26, 29, 30] 105/431 70/431 1.50 (1.15, 1.96) 0.003 1.00 2 [26, 29] 94/321 67/321 1.40 (1.07,1.84) 0.014 0.81
  1. no. number, CI confidence interval, ICS inhaled corticosteroids, FABA fast-onset-acting β2-agonist, ICS/FABA inhaled corticosteroids/fast-onset-acting β2-agonist